Oct 15 2015
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it will be presenting at the 14th Annual BIO Investor Forum being held October 20-21, 2015, at the Parc 55 in San Francisco, California.
Jerome D. Jabbour, Co-Founder and Chief Business Officer, will present on Tuesday, Oct. 20, 2015, at 11:00 a.m. PDT (2:00 p.m. EDT).
As part of his presentation, Mr. Jabbour will provide an update on the NIH/NIAID-funded Phase 2a clinical study of the Company’s lead drug candidate MAT2203, an orally-administered, encochleated formulation of the broad spectrum fungicidal medication amphotericin B. The Company recently received approval from the Institutional Review Board (IRB) of the National Institutes of Health (NIH) for the MAT2203 study and patient enrollment is expected to commence in the fourth quarter of 2015.
Mr. Jabbour will also discuss the Company’s development plans for MAT2501, an orally administered, encochleated formulation of the broad spectrum aminoglycoside antibiotic amikacin to treat gram-negative bacterial infections and intracellular bacterial infections.
A live audio webcast of the presentation will be available on the Company’s website (www.matinasbiopharma.com) in the Investor Relations section of the Events page. The webcast will be available approximately two hours after the presentation ends and will be accessible for one month.
About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. The 14th Annual BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections. The Company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead drug candidate is MAT2203, an orally-administered, encochleated formulation of amphotericin B (a broad spectrum fungicidal agent). The Company also intends to file an investigational new drug application (IND) for MAT2501, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for gram-negative and intracellular bacterial infections. In addition, the Company is exploring development and partnership options for MAT9001, a prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia, which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoproteins and PCSK9 levels.
The Company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulation technology.